

Annual Scientific Congress of Malaysian Oncological Society

11th - 13th October 2024

Setia SPICE
Convention Centre, Penang



Welcome Message by Organising Chairperson



Dear Esteemed Participants,

On behalf of the organizing committee, it is with great pleasure and anticipation that I extend a warm welcome to all distinguished attendees of the 35th Annual Scientific Congress of the Malaysian Oncological Society (ASCOMOS 2024), scheduled to take place from the 11th to the 13th of October 2024 at the Setia SPICE Convention Centre in Penang.

This year, our esteemed society eagerly awaits the gathering of leading minds, dedicated researchers, and passionate practitioners in the field of oncology. The ASCOMOS 2024 promises to bring you the most up to date science, data, and interactive lectures. We know when science meets reality, best science does not always equal perfect clinical outcomes. As such, this year we want to bridge the gap, bringing various stakeholders together to address many issues in our oncology practice, especially those related to pharmaco-economy and training.

Whether you are consultants, registrars, medical officers or even allied health, we invite you to submit an abstract for our poster presentation sessions. This is an excellent opportunity to share your latest research findings and engage with fellow colleagues in a dynamic and interactive setting.

Amidst the stunning backdrop of Penang, renowned for its rich cultural heritage and breathtaking landscapes, I encourage you to take some time to indulge in the local charm and explore the unique offerings of this vibrant city.

We look forward to your active participation, as we collectively strive to make a meaningful impact in the realm of oncology.

With warm regards,

Dr Ang Soo Fan

Organising Chairperson
35th Annual Scientific Congress of Malaysian Oncological Society
(ASCOMOS 2024)



35th ASCOMOS 2024 Organising Committee

Organising Chairperson Ang Soo Fan

Scientific Chairperson Fong Chin Heng

Scientific Committee Doris Chow Sze Ying

Ho Kean Fatt

Shazril Imran Shaukat Soo Hoo Hwoei Fen

Treasurer Soo Hoo Hwoei Fen

Subcomittee Lee Fong Wan

Tan Joon Ching

Meelashini Letchumanan

Lim Lih Chie Muhammad Fairuz Lee Chia Hui

Syahida Nafisyah Abd Hadi

Kiley Loh

Cheah Soon Keat

Congress Dinner Chairperson Doris Chow Sze Ying

Congress Dinner Committee Ifa Farhana Adnan

Nilasha Krishnan Yeoh Yun Xuan Tan Chuan Ye Oong Jie Fei

Abstract Reviewer Nur Fa'izah Ab. Muin

Ngu Ming Ruey Najihah Abu Bakar Hafizah Zaharah Ahmad Eznal Izwadi Mohd Mahidi Nahjatul Kursyiah Abd Ghafar

Oral & Poster Judges Ros Suzanna A Bustamam

Azura Deniel Fuad Ismail



CONGRESS INFORMATION

OFFICIAL CONGRESS VENUE

LG, Setia SPICE Convention Centre, No 108C, Jalan Tun Dr Awang, 11900 Penang, Malaysia

PARTICIPANT AND SPEAKER REGISTRATION COUNTER OPENING HOURS

10th October 2024, Thursday 2.30pm to 5.00pm

11th October 2024, Friday 8.00am to 6.00pm

12th October 2024, Saturday 8.30am to 6.00pm

13th October 2024, Sunday 8.30am to 2.00pm

SPEAKER READY ROOM

10th October 2024, Thursday 2.30pm to 5.00pm

11th October 2024, Friday 8.00am to 6.00pm

12th October 2024, Saturday 8.30am to 6.00pm

13th October 2024, Sunday 8.30am to 2.00pm

CPD POINTS

20 MMA CPD points will be awarded to all delegates who attend the congress. The organiser will submit the attendance list to the respective bodies for CPD accreditation I week post conference.

E-CERTIFICATE OF ATTENDANCE AND PRESENTATION. INVOICE AND RECEIPT

E-Certificate of Attendance, and Presentation as well as Invoice and Receipt will be available on your delegate dashboard for 1 month post conference. Please download the documents needed before 18th November 2024.

PARKING

Flat Rate is RM8.00 nett per day. Use TNG, Credit / Debit Card. No validation required.

SURAU

Lower Ground Floor on the way to Amari Hotel.

NEAREST MOSQUE FOR FRIDAY PRAYERS


- · Umar Ibnu Al-Khattab Mosque
- Al-Ittifaq Mosque Both are 5 to 10 minutes away by car.

LANYARD CATEGORIES

Only those with lanyards and name tags will be allowed into the conference area.



VENUE AND BOOTH LAYOUT



Roche Malaysia	Merck	Penang Hospice	BeiGene Singapore
P2 Bristol-Myers Squibb	G10 Gene Solutions Genomics	B08 Compai Healthcare	B26 Juniper Biologics
P3 & P4 AstraZeneca	F1 Duopharma	B09 DKSH	B27 Dr. Reddy's Laboratories
P5 Merck Sharp & Dohme (MSD)	F5 Synape	B10 Varian	B28 Novugen
G1 Servier	F6 Celltrion F10	B13 GENETIX Cancer Research Malaysia	B29 Camber & Laboratories (Hetero)
G2 ZP Therapeutics	Astellas B01	B14 Caris Hospice	B30 Oncode
G3 Ipsen	Kotra Pharma B02	B15 Adipolabs	Mini Session:
G4 Johnson & Johnson	OEP Group	B16 Takeda	Nurse Speaker
G5 Eisai-MSD	IDB Resources	B17 Transmedic	Ready Room Mini Session:
G6 Novartis	B04 KYAN Technologies	B21 AGTC Genomics	Physicians & Trainees
G7 Pfizer	B05 National Cancer Society Malaysia	B22 IHH Healthcare	Secretariat Room
G8	B06	B23	MOS Members Lounge

Brainlab



Amgen

Cancer Survivors

Malaysia (CSM)



Aaron Hiew Wi Han



Adel Zaatar




Adlinda Alip



Ahmad Kusyairi Khalid



Ahmad Radzi Ahmad Badruddin



Alex Khoo Cheen Hoe



Amir Shah



Ang Soo Fan



Angel Kwan Khor Nee



Au Mun Yee



Azura Deniel



B V Murali Krishna



Chan Ming Jun



Cheah Soon Keat



Chew Ghee Kheng



Chittawan Poonsiri



Chong Kwang Jeat



Choong Swee Hsia



Chow Poh Lee



Daniel Chan



Daniel Gan Eng Hwee



David Lee Dai Wee



Doris Chow



Eng Jie Yi



Eunice Ong Song-En





Eznal Izwadi Mohd Mahidin



Fabian Lee



Flora Chong Li Tze



Fong Chin Heng



Fuad Ismail



Ghassan Abou Atfa



Gokula Kumar



Gunasundari Sathival



Hafizah Zaharah



Hayani Abdul Wahid



Ho Gwo Fuang



Ho Kean Fatt



Ibtisam Md Nor



Ivy Ho Chiak Vun



Izzati Wan Maharuddin



Jaishree Sharmini Jivanadham



James Khaw Chern Wern



Jasjit Singh Nijhar



Jeffrey Clarke



Jennifer Leong Siew Mooi





Jimmy Hendrick Anak Kijon



John Chia Whay Kuang



Junya Fukuoka



Kevin Hew Poh Wai



Khairiyah Sidek



Kiley Loh



Tan Hsio Ching




Lee Cheen Leng



Lee Chia Hui



Lee Fong Wan



Lem Li Khen



Leong Kin Wah



Liam Chong Kin



Lim Liang Yik



Lim Shyang Yee



Lim Yueh Ni



Loh Kok Beng



Loo Chia Ming



Marfu'ah Nik Eezamuddeen





Maria Hawkins



Marniza Saad



Mastura Md Yusof



Matin Mellor



Meelashini Letchumanan



Melvin Chua Lee Kiang



Michael Chao



Mohamed Ali Abdul Khader



Mohamed Ibrahim A Wahid



Mohd Khairul Mohd Zambri



Mohd Razif Mohamad Yunus



Muhammad Azrif Ahmad Annuar



Ngu Ming Ruey



Noor Zafifah Zakaria



Najihah Abu Bakar



Nellie Cheah Lay Chin



Nahjatul Kursyiah Abd Ghafar



Norhashimah Khadir



Nur Fadhlina Abdul Satar



Nur Fa'izah Ab Muin



Nuradh Joseph





Oo Loo Chan



Ooi Kai Yun



Patricia Shamani Soosainathan



Prashant Narhari



Prathepamalar Yehgambaram



Punitha Arumohan



Qym Ho



Rachel Ann Cooper



Ravindran Kanesvaran



Rizma Mohd Zaid



Robin Hill



Rosmawati Mohamed



Ros Suzanna A Bustamam



Rozita Abdul Malik



Rufus Jessusdas



Samuel Ow



Sangeeta Vahnalingam



Saw Min Hong



Sazrah Shuib



Shazril Imran



Sith Sathornsumetee





Soo Hoo Hwoei Fen



Soon Sing Yang



Sou Jing Kim



Suhana Yusak



Tan Ai Lian



Tan Boon Seang



Teoh Mei Shi



Thiraviyam Elumalai



Tom Roques



Vaishnavi Jeyasingam



Voon Pei Jye



Wan Zamaniah Wan Ishak



Winnie Ong Peitee



Wong Yoke Fui



Yap Beng Khiong



Yeoh Kheng Wei



Yoon Chee Kin



Yoon Sook Yee



Zulaikha Jamalludin







35th Annual Scientific Congress of the Malaysian Oncological Society

For more information, Visit www.ascomos.com

10 OCTOBER 2024THURSDAY

PRE-CONGRESS WORKSHOP: TRAINING the TRAINERS Clinical Oncology

The Training the Trainers (TtT) workshop is intended for consultants and specialist trainers / supervisors from clinical oncology. There will be asynchronous mode of instructional delivery using instructional videos which will be sent to the participants prior to the synchronous online or onsite sessions. The synchronous sessions will have short interactive lectures, discussions and small group activities. This workshop intends to equip the participants with the minimum essential knowledge, skills and attitudes required to function as an effective trainer for postgraduate medical training.

Training for the TtT directors is intended for the identified course directors from each speciality. The TtT course directors will be the first group of trainers who will initiate and coordinate the NPMC TtT in their respective disciplines.

	Programme		
0845 - 0900	Registration & Tea		
	Morning Session	Chairperson: Wong Yoke Fui	
0900 – 0915	Welcome and Introduction	Marniza Saad & Soo Hoo Hwoei Fen	
0915 – 0945	Lecture 1: The Effective Supervisor	Rachel Cooper	
0945 – 10:15	Lecture 2: How to Give Constructive Feedback that Leads to Positive Changes?	Tom Roques	
10:15 – 11:00	Break & Photo Taking		
11:00 – 12:00	Skill Activity 1: Giving Constructive Feedback	Tom Roques & Rachel Cooper + All facilitator	
12:00 – 12:30	Lecture 3: Teaching Clinical Reasoning in a Busy Practice	Marniza Saad	
12:30 - 13:15	Lunch & Prayer		
8	Afternoon Session	Chairperson: Nur Fadhlina Abdul Satar	
13:15 – 13:45	Lecture 4: Assessment, Evaluation & Appraisal	Fong Chin Heng	
13:45 – 14:30	Skill Activity 2: WBA: Conducting & Appraising CBD with trainees	Wong Yoke Fui & Fong Chin Heng + All facilitator	
14:30 – 14:45 Break 14.45 –15:30 Lecture 5: Cost Effectiveness in Oncology Management		A I	
		Chittawan Poonsiri + All facilitator	
15:30 – 16:00	Lecture 6: Coaching Trainee in Era with Abundance of Online Resources	Melvin Chua	
16.00 – 17.00	Tea & Closing		
19.00 – 22.00	Faculty Dinner		



Dening Ceremony

1045 - 1055

Welcome Remarks Negaraku & Doa Recital

1055 - 1100

Welcome Speech
Dr Ang Soo Fan

Organising Chairperson of ASCOMOS 2024

1100 - 1105

Welcome Speech
Dr Muthukkumaran Thiagarajan

President of Malaysian Oncological Society

1105 - 1110

VIP Speech

Yang Berhormat Daniel Gooi Zi Sen

Penang Health Exco Member of the Penang State Executive Council (Youth, Sports and Health)

1110 - 1120

Launch of ASCOMOS 2024

1120 - 1135

Signing of MOU Between RCR and MOS Launching of FRCR Exam Center

Programme Overview

DAY 1: 11 OCTOBER 2024 (FRIDAY)

	BALLROOM 1	BALLROOM 2	BALLROOM 3		
0800 - 0930		REGISTRATION			
0930 - 1045	GRAND FORUM: BRIDGING THE GAPS				
1045 - 1135	OPENING CEREMONY - OPENING OF ASCOMOS PENANG 2024				
1135 - 1235	KEYNOTE ADDRESS: ONCOLOGY TRAINING				
1235 - 1300	Repartitioning Of Lecture Halls				
1300 - 1400	LUNCH SYMPOSIUM BY BMS	LUNCH SYMPOSIUM BY PFIZER	LUNCH SYMPOSIUM BY MSD		
1400 - 1530	EARLY LUNG CANCER	EARLY BREAST CANCER	HEPATOBILIARY		
1530 - 1610	TEA SYMPOSIUM BY JOHNSON & JOHNSON	TEA SYMPOSIUM BY MERCK	TEA SYMPOSIUM BY ASTRAZENECA		
1610 - 1700	ADVANCED LUNG CANCER	ADVANCED BREAST CANCER	CANCER GENOMICS		
1900 - 2200	C	ONGRESS DINNER (R.S.V.P ONLY)			

MOS Members Lounge is open from 0900 - 1700



DAY 1: 11 OCTOBER 2024 (FRIDAY)









DAY 1: 11 OCTOBER 2024 (FRIDAY)



ASCOMOS 2024 Tea Symposium Shaping The Future: Recent Breakthroughs in mCRC treatment 11th October 2024 (Fri) | 3:30PM - 4:10PM | Ballroom 2 Chairperson: Dr Nellie CHEAH **Dr YONG Wei Peng** onsultant Clinical Oncologist Senior Consultant, Medical Oncologist Loh Guan Lye Specialist Hospital, Penang National University Cancer Institute, Singapore MERCK Merck Sdn Bhd 198901000839 (178145-V) B-2





Aproval Date: Sept 2024 EM-185010

Programme Overview

	BALLROOM 1	BALLROOM 2	BALLROOM 3	Hospitality Suites	Hospitality Suites
0800 - 0850				MINI SESSION: ONCOLOGY IN PRACTICE FOR NURSES	MINI SESSION: TRAINEES
0830 - 0900		REGISTRATIO	N		
0900 - 0945		SCIENTIFIC PLENARY			
0945 - 1000	Tea Bre	ak And Repartitioning of Lectu	re Halls		
1000 - 1045	TEA SYMPOSIUM BY ZP THERAPEUTICS	TEA SYMPOSIUM BY PFIZER	TEA SYMPOSIUM BY SERVIER		MINI SESSION: PHYSICS
1045 - 1155	GYNECOLOGIC ONCOLOGY	LOWER GI	HEAD & NECK		
1155 - 1305	NURSING	PROSTATE	NUCLEAR MEDICINE		
1305 - 1405	LUNCH SYMPOSIUM BY ROCHE	LUNCH SYMPOSIUM BY MSD	LUNCH SYMPOSIUM BY ASTRAZENECA		
1405 - 1510	CNS	BLADDER	PHYSICS/RADIATION THERAPIST		esentation - 1530
1510 - 1555	TEA SYMPOSIUM BY NOVARTIS	TEA SYMPOSIUM BY IPSEN	TEA SYMPOSIUM BY AMGEN		Panel
1555 - 1645	RESEARCH	KIDNEY	IMMUNOTHERAPY		
1600 - 1650				MINI SESSION: ONCOLOGY IN PRACTICE FOR NURSES	
1700 - 1900	ANNUAL GENERAL MEETING (MOS MEMBERS ONLY)				


























Programme Overview


DAY 3: 13 OCTOBER 2024 (SUNDAY)

	BALLROOM 1	BALLROOM 2	BALLROOM 3	Hospitality Suites	Hospitality Suites
0800 - 0850				MINI SESSION: ONCOLOGY IN PRACTICE FOR NURSES	
0830 - 0900	REGISTRATION				
0900 - 0945	SCIENTIFIC PL	SCIENTIFIC PLENARY (III) ARTIFICIAL INTELLIGENCE			
0945 - 1000		Repartitionin	g of Lecture Halls		
1000 - 1045	TEA SYMPOSIUM BY GENE SOLUTION	TEA SYMPOSIUM BY EISAI-MSD			
1045 - 1200	UPPER GI	SARCOMA	PALLIATIVE CARE		
1200 - 1315	THYROID	FREE PAPER ORAL PRESENTATIONS	PATIENT ADVOCACY		
1315 - 1345		CLOSING	CEREMONY		



DAY 3: 13 OCTOBER 2024 (SUNDAY)





DAY 1: 11 OCTOBER 2024 (FRIDAY)

	BALLROOM 1	BALLROOM 2	BALLROOM 3
0800 - 0930		REGISTRATION	ı
0930 - 1045	Chairpersons:	GAPS eang & Suhana Yusak	
0930 - 0950	The Ideal: Comprehensive Oncolo Taking a Wider View on Improvin		Speaker: Yeoh Kheng Wei, Singapore
0950 - 1005	Singapore: Learning the Experience "Cancer Drug Reimbursement Sys		Speaker: Ravindran Kanesvaran, Singapore
1005 - 1015	Thailand: Cancer Drug Reimburse Current Landscape and Future Di		Speaker: Chittawan Poonsiri, Thailand
1015 - 1025	Malaysia: Where do We Stand in Affordability and National Cancer		Speaker: Mastura Md Yusof
1025 - 1045		Forum Discussion	
1045 - 1135	OPENING (CEREMONY - OPENING OF ASCOM	OS PENANG 2024
1135 - 1235		SS: ONCOLOGY TRAINING - What I ersons: Marfu'ah Nik Eezamuddeen & Le	
1135 - 1155	ONCOLOGY TRAINING - Wha	t Do We Need for the Future?	Speaker: Rachel Cooper, United Kingdom
1155 - 1215	National Postgraduate Medical Cu Training for the Nation	ırriculum -	Speaker: Marniza Saad
1215 - 1235	FRCR Pathway - The Journey to H	Harmony	Speaker: Soo Hoo Hwoei Fen
1230 - 1300		Repartitioning of Halls	
	LUNCH SYMPOSIUM BY BMS (III) Bristol Myers Squibb	LUNCH SYMPOSIUM BY PFIZER Pfizer	LUNCH SYMPOSIUM BY MSD MSD
1300 - 1400	Evolving Treatment Landscape in First-Line Systemic Treatment of Hepatocellular Carcinoma Chairperson: Ho Kean Fatt Speaker: Thomas Yau, Hong Kong	The Current and Future Treatment Landscape for HR+/HER2- mBC Chairperson: Kiley Loh Speaker: Tiffany A. Traina, United State of America Panelist: Mastura Md Yusof Angel Kwan Khor Nee	Enhancing MDT Collaboration in Early-Stage Resectable NSCLC for Improved Patient Outcomes Chairperson: Voon Pei Jye Speakers: Soon Sing Yang Pang Yong Kek



DAY 1: 11 OCTOBER 2024 (FRIDAY)

	BALLROOM 1	BALLROOM 2	BALLROOM 3
1400 - 1530	EARLY LUNG CANCER Chairpersons: Matin Mellor & Lem Li Khen	EARLY BREAST CANCER Chairperson: Muhammad Azrif Ahmad Annuar & Leong Kin Wah	HEPATOBILIARY Chairperson: Rosmawati Mohamed & Ibtisam Md Nor
1400 1400	Lung Cancer Screening & Smoking Cessation	Anthracyclines - Is it Still Relevant in Early Breast Cancer?	Combination Therapy in Intermediate HCC: Where We Stand?
1400 - 1420	Speaker: Liam Chong Kin	Speaker: Samuel Ow, Singapore	Speaker: Ghassan Abou Alfa, United States of America
1420 - 1440	Debate: Neoadjuvant Chemo-Immunotherapy Before Surgery Should be the SOC for Stage IB (>4cm) - IIIA NSCLC	Adjuvant Endocrine Therapy in Premenopausal Women - Beyond Tamoxifen	Indications of SBRT in Hepatobiliary Cancer, Clinical Aspects of Radiotherapy Planning
	Proponent: Cheah Soon Keat Opponent: Soon Sing Yang	Speaker: Kiley Loh	Speaker: Maria Hawkins, United Kingdom
1440 - 1500	How Do I Treat Stage III NCLSL	Role of RT/Axillary Treatment in the Era of Neoadjuvant Therapy	MDT Case Discussion Speakers:
	Speaker: Michael Chao, Australia	Speaker: Mastura Md Yusof	Lim Yueh Ni Loh Kok Beng Jasjit Singh Nijhar
1500 - 1530	Q&A	Q&A	Q&A
	TEA SYMPOSIUM BY JOHNSON & JOHNSON Johnson & Johnson	TEA SYMPOSIUM BY MERCK	TEA SYMPOSIUM BY ASTRAZENECA
1530 - 1610	From Progression to Possibilities: Shaping Tomorrow's Management in EGFRm NSCLC	Shaping the Future: Recent Breakthrough in mCRC treatment	AstraZeneca EGFR-TKI Combination Treatment; Who to Gain, at What Cost? Chairperson:
	Chairperson: Voon Pei Jye Speaker: Molly SC Li, Hong Kong	Chairperson: Nellie Cheah Speaker:	Ho Gwo Fuang Speaker: Cheah Soon Keat





DAY 1: 11 OCTOBER 2024 (FRIDAY)

	BALLROOM 1	BALLROOM 2	BALLROOM 3
1610 - 1700	ADVANCED LUNG CANCER Chairpersons: Amir Shah & Hayani Abdul Wahid	ADVANCED BREAST CANCER Chairpersons: Kiley Loh & Rozita Abdul Malik	CANCER GENOMICS Chairpersons: Chong Kwang Jeat & Nur Fa'izah Ab Muin
1610 - 1630	Management of Oligometastatic Disease in Lung Cancer	Weighing the Cost and Benefits of Novel Therapies in Metastatic Breast Cancer	Genetic Testing in Clinic: a Practical Guide
	Speaker: David Lee Dai Wee	Speaker: Ho Gwo Fuang	Speaker: Yoon Sook Yee
1630 - 1650	Post-Progression Management for Advanced NSLCL with Driver Mutation Pre-treated with TKI Speaker: Jeffrey Clarke, United States of America	MDT Case Discussion Speakers: Samuel Ow, Singapore Teoh Mei Shi Ivy Ho Ho Gwo Fuang	Riding the Genomic Wave: Cancer Genetics and Therapy Speakers: Winnie Ong
1650 - 1700	Q&A	Q&A	Q&A
1700 ONWARDS	END OF DAY 1		
1900 - 2200	CONGRESS DINNER (R.S.V.P ONLY)		

MOS Members Lounge is open from 0900 - 1700




	BALLROOM 1	BALLROOM 2	BALLROOM 3	
0830 - 0900		REGISTRATION		
0900 - 0945	SCIENTIFIC PLENARY (IV) RESEARCH Chairpersons: Soo Hoo Hwoei Fen & Hafizah Zaharah			
0900 - 0943	Overcoming Challenges In Onc (Phase 1-3) In Malaysia	cological Clinical Trials	Speaker: Voon Pei Jye	
0945 - 1000		Repartitioning of Halls		
	TEA SYMPOSIUM BY ZP THERAPEUTICS	TEA SYMPOSIUM BY PFIZER	TEA SYMPOSIUM BY SERVIER	
	THERAPEUTICS making healthcare more accessible	₹ Pfizer	SERVIER	
1000 - 1045	New Treatment Landscape in HR+ HER2- eBC: Reducing the Risk of Recurrence for High-Risk eBC Patients with Aabemaciclib Chairperson: Kevin Hew Poh Wai Speaker: Joyce O'Shaughnessy, United State of America Case Presentation: Kiley Loh	Unveiling the Future: Redefining Lung NSCLC ALKare into Chronic Disease Chairperson: Jennifer Leong Speakers: Ignatius Ou Sai-Hong, United State of America & Fuad Ismail	Navigating the Pancreatic Cancer Treatment Landscape: The Asian Experience Chairperson: Nellie Cheah Lay Chin Speaker: Masafumi Ikeda, Japan	
1045 - 1155	GYNECOLOGIC ONCOLOGY Chairpersons: Fabian Lee & Ooi Kai Yun	LOWER GI Chairpersons: Ahmad Radzi Ahmad Badruddin & Rizma Mohd Zaid	HEAD & NECK Chairpersons: Gokula Kumar Appalanaido & Eznal Izwadi Mohd Mahidin	
1045 - 1105	Endometrial Cancer – Landmark Trials & Biomarker Directed Therapies Speaker:	Neoadjuvant Strategies for Locally Advanced Rectal Cancer - TNT, How to Implement This in Malaysia Speaker:	Reinventing the Wheel for Radiotherapy in Nasopharyngeal Carcinoma Speaker:	
	John Chia Whay Kuang, Singapore	Patricia Shamani Soosainathan	Melvin Chua, Singapore	
1105 - 1125	New Standard of Care for Locally Advanced and Metastatic Cervical Cancer	Management of Colorectal Peritoneal Mets: HIPEC is Not Hot Air	Transoral Robotic Surgery - Malaysian Experience Speaker:	
	Speaker: Jennifer Leong	Speaker: James Khaw Chern Wern	Mohd Razif Mohamad Yunus Ahmad Kusyairi Khalid	





DAY 2: 12 OCTOBER 2024 (SATURDAY)

	BALLROOM 1	BALLROOM 2	BALLROOM 3
1125 - 1145	MDT Cases Discussion: Stage I Ovarian, Recurrence Ovarian on PARP-i, Locally Advanced Cervical, Carcinosarcoma of Uterus; Metastatic Endometrial Cancer etc Presenter: Ang Soo Fan Panel: Jennifer Leong John Chia Whay Kuang, Singapore Chew Ghee Kheng	Updates Systemic Therapy for Metastatic Colorectal Cancer Speaker: Nur Fadhilina Abdul Satar	Metastatic Head and Neck Carcinoma - Changing Treatment Paradigm Speaker: Wan Zamaniah Wan Ishak
1145 - 1155	Q&A - 10 minutes	Q&A	Q&A
1155 - 1305	NURSING Chairpersons: B V Murali Krishna & Qym Ho	PROSTATE Chairpersons: Kevin Hew & Vaishnavi Jeyasingam	NUCLEAR MEDICINE Chairpersons: Mohamed Ali Abdul Khader & Izzati Wan Maharuddin
	Optimal Care of Vascular Implanted Devices	Hypofractionated or Ultrahypofractionated Prostate Radiotherapy?	Diagnostic Nuclear Medicine for Solid Tumours in Malaysia
1155 - 1215	Speaker: Punitha Arumohan	Speaker: Thiraviyam Elumalai, United Kingdom	Speaker: Au Mun Yee
1215 1225	Optimal Management of Fungating Breast Wound	Dosimetric Advantages of Spacers in Prostate Radiotherapy	Therapeutic Nuclear Medicine for Solid Tumours in Malaysia
1215 - 1235	Speaker: Norhashimah Khadir	Speaker: Michael Chao, Australia	Speaker: Alex Khoo Chee Hoe
1255 - 1305	Q&A	O&A	Q&A



Continue to Next Page >



	BALLROOM 1	BALLROOM 2	BALLROOM 3
	LUNCH SYMPOSIUM BY ROCHE	LUNCH SYMPOSIUM BY MSD MSD	LUNCH SYMPOSIUM BY ASTRAZENECA
1305 - 1405	Evolving Paradigm in Unresectable HCC: Western vs Asian Perspectives Chairperson: M. Amir Shah Speaker: David James Pinato, United Kingdom Ho Gwo Fuang Panelist: Lim Chun Sen Jennifer Leong	Advancing Gastric and GEJ Cancer Management: Multidisciplinary Insights into Immunotherapy and Biomarkers Moderator: Kong Hwai Loong, Singapore Speaker: Kelvin Voon Case Presenters: Yong Wei Peng, Singapore Ho Kean Fatt	Navigating the HER2 Spectrum in Metastatic Breast Cancer: Shifting Perspectives Chairperson: Doris Chow Speakers: Samuel Ow, Singapore & Mastura Md Yusof
1405 - 1510	CNS Chairpersons: Doris Chow & Daniel Gan	BLADDER Chairpersons: Shazril Imran & Najihah Abu Bakar	PHYSICS/RADIATION THERAPIST Chairpersons: Meelashini Letchumanan & Lee Chia Hui
1405 - 1425	Tumour Treating Fields (TTF) for the Management of Glioma - The Asian Experience	Cost Effective Treatment for Muscle Invasive Bladder Cancer for Developing Countries	SBRT Liver Motion Management Practice in Malaysia (Radiation Therapist Perspective)
	Speaker: Daniel Chan, Singapore	Speaker: Nuradh Joseph, Sri Lanka	Speaker: Mohd Khairul Mohd Zambri
1425 - 1445	Is There a Role for Targeted Therapy in Gliomas?	Is Radiosensiting Radical Radio- therapy in Bladder, Superior Than Surgery?	Overcoming Challenges in SBRT for the Spine
1723 - 1773	Speaker: Sith Sathornsumetee, Thailand	Speaker: Thiraviyam Elumalai, United Kingdom	Speaker: Zulaikha Jamalludin
1445 1505	Management of G2/3 Glioma or Case Discussion	Optimal Management of Metastatic Urothelial Carcinoma	SBRT for Challenging Sites: Intrahepatic, Renal, and Pericardial Lesions
1445 - 1505	Speaker: Sith Sathornsumetee, Thailand	Speaker: Ravindran Kanesvaran, Singapore	Speaker: Robin Hill, Australia





DAY 2: 12 OCTOBER 2024 (SATURDAY)

	BALLROOM 1	BALLROOM 2	BALLROOM 3
1505 - 1510	Q&A	Q&A	Q&A
1510 - 1555	TEA SYMPOSIUM BY NORVATIS NOVARTIS Bridging the Chasm: Unmet Needs and Innovations in HR+ HER2- Breast Cancer Care Chairperson: Mastura Md. Yusof Speaker: Sherene Loi, Australia Panelist: Kiley Loh	TEA SYMPOSIUM BY IPSEN IPSEN Kidney Cancer Puzzles: Breakthroughs and Trends 2024 Chairperson: Marniza Saad Speakers: Cristina Suarez, Spain Ooi Po Lin	TEA SYMPOSIUM BY AMGEN AMGEN AMGEN Real-World Approaches to Treating KRAS G12C NSCLC Chairperson: Yap Beng Khiong Speaker: Jeffrey Clarke, United State of America Emerging Strategies for Managing KRAS Mutation in mCRC Chairperson: Cheah Soon Keat Speaker: Choo Su Pin, Singapore
1555 - 1645	RESEARCH Chairpersons: Sangeeta Vahnalingam & Ngu Ming Ruey	KIDNEY Chairpersons: Adel Zaatar & Flora Chong Li Tze	IMMUNOTHERAPY Chairpersons: David Lee Dai Wee & Saw Min Hong
1555 - 1615	Implementing Radiotherapy Related Research in a Developing Country Speaker: Nuradh Joseph, Sri Lanka	Adjuvant Therapy in Renal Cell Carcinoma: Where Do We Now Stand? Speaker: Adlinda Alip	Updates in Predictive Markers for Immunotherapy and Treatment of Solid Tumours Speaker: Lee Fong Wan
1615 - 1635	Delivering Support for a Successful Investigator Initiated Research in Oncology Speaker: Yoon Chee Kin	Systemic Therapy Metastatic Renal Cell, Sequencing Optimal Therapy Speaker: Lee Cheen Leng	Recognising Rare and Lethal Immunotherapy Related Adverse Events and Management Speakers: Nellie Cheah Lay Chin & Tan Hsio Ching
1635 - 1645	Q&A	Q&A	Q&A
1645 ONWARDS		END OF DAY 2	
1700 - 1900	ANNU	AL GENERAL MEETING (MOS ME	MBERS ONLY)

7

MOS Members Lounge is open from 0900 - 1700



DAY 3: 13 OCTOBER 2024 (SUNDAY)


	BALLROOM 1	BALLROOM 2	BALLROOM 3		
0830 - 0900		REGISTRATION			
0900 - 0945	SCIENTIFIC PLENARY (III) ARTIFICIAL INTELLIGENCE Chairpersons: Fong Chin Heng & Lee Fong Wan				
	Improving Cancer Diagnostics and Therapeutics Using Artificial Intelligence - Current State of Affair and Future Potentials		Speaker: Junya Fukuoka, Japan		
0945 - 1000	Repartitioning of Halls				
1000 - 1045	TEA SYMPOSIUM BY GENE SOLUTION GENE SOLUTIONS The Dynamic ctDNA: Minimal Residual Disease & Beyond - Monitoring & Clinical Applications Speaker: Nguyen Duy Sinh, Vietnam	TEA SYMPOSIUM BY EISAI-MSD Like human health care The Journey of Optimizing Systemic Treatment for Advanced RCC Chairperson & Panelist: Cheah Soon Keat Speaker: Marniza Saad Case Presenter: Lee Hui Jin			
1045 - 1200	UPPER GI Chairpersons: Prathepamalar Yehgambaram & Sou Jing Kim	SARCOMA Chairpersons: Ho Kean Fatt & Angel Kwan	PALLIATIVE CARE Chairpersons: Jaishree Sharmini Jivanadham & Noor Zafifah Zakaria		
1045 - 1105	Oligomets in Upper GI Cancer - Any Role of Surgery? Speaker: Lim Shyang Yee	GIST Updates Speaker: Wong Yoke Fui	National Pain Management CPG (2nd Edition) Speaker: Aaron Hiew Wi Han		
1105 - 1125	Peri-Operative Treatment in Upper GI Cancer Speaker: Eng Jie Yi	Giant Cell Tumours - an Update Speaker: Prashant Narhari	Dying Well - Myth or Possibility Speaker: Oo Loo Chan		
1125 - 1145	Radiotherapy For UGI CA - Current Status and Future Direction Speaker: Maria Hawkins, United Kingdom	Managing "Whoops!" Surgery Speaker: Tan Ai Lian Prashant Narhari	Advanced Care Plan - What is it? Speaker: Lim Liang Yik		
1145 - 1200	Q&A	Q&A	Q&A		

Continue to Next Page >



DAY 3: 13 OCTOBER 2024 (SUNDAY)

	BALLROOM 1	BALLROOM 2	BALLROOM 3
1200 - 1315	THYROID Chairpersons: Yap Beng Khiong & Chan Ming Jun	FREE PAPER ORAL PRESENTATIONS Chairpersons: Eunice Ong & Rufus Jessusdas	PATIENT ADVOCACY Chairpersons: Chow Poh Lee & Gunasundari Sathivaloo
1200 - 1220	Sequencing Therapies for Metastatic Thyroid Carcinoma Speaker:	Free Paper Oral Presentation (Please refer to page 32 for the presenters' name) Judges: Ros Suzanna A Bustamam Azura Deniel Fuad Ismail	Navigating Public Healthcare With a Diagnosis of Cancer Speaker: Sazrah Shuib
1220 - 1240	Management of Low Risk Thyroid Carcinoma Speaker:		Where to Find Support After Diagnosis of Cancer? Speaker:
	Alex Khoo Cheen Hoe		Jimmy Kijon
1240 - 1300	Anaplastic/Poorly Differentiated Thyroid Carcinoma - What are Our Options		Living with Terminal Cancer - How to Carry On
	Speaker: Choong Swee Hsia		Speaker: Loo Chia Ming
1300 - 1315	Q&A	Judging Session	Q&A
1315 - 1345	CLOSING CEREMONY		



Free Paper Oral Presentation

DAY 3: 13 OCTOBER 2024 1200 - 1300 BALLROOM 2

Outcome And Transcriptomic Features of Dual EGFR And MET Blockade In NSCLC

Presenter:

David Dai-Wee Lee

Ng WP, Ang SF, Lau DP, Wan LY, Lai GGY, Boey MYW, Lim TKH, Tan DSW

Leveraging Phenomic and Genomic Data from a Large-Scale Cohort Study in Advancing Personalized Oncology – A preliminary UK Biobank Analysis

Presenter:

Shirin Tan Hui

Lai WH, Sim EUH, Voon PJ

Cabozantinib Plus Nivolumab (C+N) Vs Sunitinib (S) For 1st Line Advanced Renal Cell Carcinoma (ARCC): 55.6 Month Follow-Up Of The Checkmate 9ER Trial

Presenter:

Ankush Kalra

Bourlon MT, Escudier B, Burotto M, Powles T,4 Apolo AB, Shah AY, Porta C, Suárez C, Barrios CH, Richardet M, Gurney H, Kessler ER, Tomita Y, Bedke J, Wang F, Wang P, Panzica J, Fedorov V, Motzer RJ, Choueiri TK

Improved BRCA Prediction For Asian Breast Cancer Patients

Presenter:

Boon Hong Ang

Wong ZL, Tai MC, Ng PS, Yoon SY, Hasan SN, Lim JMC, Hassan NT, Padmanabhan H, Lee VYM, Mohd Taib NA, Yip CH, Hartman M, Lim SH, Tan EY, Tan BKT, Tan SM, Tan VKM, Ho PJ, Khng AJ, Li J, Loh SHS, Teo SH, Ho WK

Judges:

Ros Suzanna A Bustamam Azura Deniel Fuad Ismail

Personalized Mutation Tracking In Circulating-Tumor DNA Predicts Recurrence In Patients With High-Risk Early Breast Cancer

Presenter:

Van-Anh Nguyen Hoang

Nguyen ST, Nguyen Trieu V, Nguyen DS, Tu LN

Oncologists' Evaluation Of The Framework Of Strategies For Managing Chemotherapy-Induced Nausea And Vomiting (CINV)

Presenter:

Nurul Suhaida Badarudin

Mohamed Shah N, Ismail F, Islahuddin F, Mohd Tahir NA

Swallowing Assessment in Patients with Oral Tongue Squamous Cell Carcinoma (OTSCC) Treated with Upfront Brachytherapy versus Surgery

Presenter:

Muhamad Yusri Musa

Ong KP, Mohamad I, Gokulakumar A, Jalil J, Zahri M, Fakhrurozi M

Avelumab First-Line Maintenance For Advanced Urothelial Carcinoma: Real-World Results From The Early Access Program In Malaysia

Presenter:

John Low

Ismail F, Abdul Wahid MI, Thiagarajan M, Tan AL, Chin NCL, Lam KS, Chow SY, Ang SF, Ng M, Loke H



12 OCTOBER 2024 1400 - 1530 FOYER AREA

Poster Presentation

HRQOL With Tepotinib In Patients With ME-Tex14 SKIPPING NSCLC With Brain, Liver, Adrenal Or Bone Metastases In The Phase II Vision Trial

Presenter:

Tho Lye Mun

Reinmuth N, Mazieres J, Popat S, Paz-Ares L, Hook E, Hatswell A, Vlassak S, Johne A, Vioix H, Paik P

Updated Results Of Phase 3 Glow Study Evaluating Zolbetuximab + Capox In CLDN18.2+ HER2- Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma

Presenter:

J

Hoo HFS, Lordick F, Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, Van Cutsem E, Plazas JG, Huang J, Shen L, Oh SC, Sunpaweravong P, Turk HM, Park JW, Moran D, Bhattacharya P, Cao Y, Xu RH

Prevalence Of HER2-Low Breast Cancer Patients In Subang Jaya Medical Centre (SJMC)

Presenter:

Sum Yee Ling

Sum YL, Yap NY, Ariffen NA, Sukri NS, Sairan NA, Rajadurai P, Cheah YK

Bioinformatics Analyses To Elucidate Metastasis-Related Genes In Metastatic Nasopharyngeal Carcinoma (NPC)

Presenter:

Loo Ee Mun

Tan BS, Leong WM, Leong CO, Mai CW

Judges:

Ros Suzanna A Bustamam Azura Deniel Fuad Ismail

Patient Scalp Cooling Experiences

Presenter:

Tan King Mee

Lau J, Loh K

Cytogenetics Abnormalities Observed Among Multiple Myeloma Patients In Malaysia

Presenter:

Muhammad Nur Arif Nor Azan

Yap MMHP, Rosmanizam SLA, Chan PZ, Abdul Raub SH, Noor Akmal S, Muhammed MH

Real-World Treatment Patterns and Effectiveness of Subsequent Treatments Following First-line (1L) Brigatinib For Patients With ALK+ NSCLC

Presenter:

Ahmet Melih Kurec

Delmonte A, Ahn MJ, Ghosh S, Hochmair M, Yang TY, Yang JCH, Han JY, Hansen KH, Wu Y, Wan Y, Lin HM, Kretz J, Hupf B, Churchill EN, Fram RJ, Cabasag CJ, Goriya V, Zhao Y, Campelo MRG

Software For Automated Calculation Of PTV Margins From CBCT-Based IGRT Protocols

Presenter:

Mohd Hafiz Mohd Zin

Mazlan NA, Abubakar A, M Zamri NA, Shaukat SI



Poster Presentation

DAY 2: 12 OCTOBER 2024 1400 - 1530 FOYER AREA

Beaming Miracle – The Triumph Of Radiotherapy In Battling Condyloma Acuminatum. A Case Report

Presenter:

Ch'ng Wan Ping

Mohamad NN

Amicable Response In Combining Systemic Therapies And Selective Internal Radiation Therapy (SIRT) In Inoperable Primary And Secondary Liver Tumours: Case Series

Presenter:

Boey Ching Yeen

Sulaiman Shah AA, Yee MLS, Aslum Khan F

Real-World Application Of A Multicancer Early Detection Test To Detect Cancers Lacking Recommended Screenings

Presenter:

Hanh Nguyen

Nguyen TT, Nguyen DLH, Phan MN, Tieu LB, Nguyen SD, Tang SH, Tran SL

A Case Report Of Esophageal Alk-Expressing Inflammatory Myofibroblastic Tumour (IMT) Treated With Crizotinib In A Patient With A History Of Mediastinal Mixed Germ Cell Tumour

Presenter:

Nilasha Krishnan

Fong CH





Date & Time

Saturday, 12 October 2024 08:00 am - 09:00 am

Where

Hospitality Suite 2, Level LG, Setia Spice Penang.

Who

Oncology trainees (MOS members)

Agenda

 General election for trainee group committee and MOS trainee reps for 2024-2025.

• MOS trainee membership drive

Join us for our first session to help shape the future of this community!

You may also join us virtually via zoom

https://shorturl.at/vETj6





Annual Scientific Congress of Malaysian Oncological Society





ONCOLOGY PRACTICE FOR NURSES

Saturday, 12 October 2024 Sunday, 13 October 2024



JOIN NOW

MODULES COVERED



Module 1 Chemoport care and flushing



Module 2 Oncology drug injection



Module 3 Choosing the right wigs

For Registered Participants of This Session Only

WORKSHOP SESSIONS

SATURDAY 12 OCTOBER 2024

8.00am to 8.50am

Registration time: 7.45am

SATURDAY 12 OCTOBER 2024

4.00pm to 4.50pm

Registration time: 3.50pm

SUNDAY 13 OCTOBER 2024

8.00am to 8.50am

Registration time: 7.45am







PERSPECTIVE:

CURRENT AND FUTURE OF PATIENT-SPECIFIC QUALITY ASSURANCE AND MONITORING FOCUSING ON SGRT AND SECONDARY DOSE CHECK



SESSION FOR MEDICAL PHYSICIST & RADIATION THERAPIST

9.45AM - 10.45AM PRESENTATION & DEMO 10.45AM - 11.15AM SHARING/NETWORKING SESSION



Hidayat Ghani
MSc, Medical Physics
Product Specialist
LAP Laser Applications
Asia Pacific



Hospitality Suite 2, Level LG, Setia Spice Penang



SCAN HERE
TO REGISTER NOW!



12 October 2024 (Saturday) 9.45am - 11.15am

ASCOMOS HIKE FOR FUN

Embark on a FUN journey together



Gathering point: Bukit Jambul Hiking Trail Entrance

Gathering time: 5:50 AM

Hiking Begins: 6:00 AM

Elevation: 335 meters, Duration: 40 minutes

13 OCTOBER

6:00AM - 7:30AM



To Our Sponso

Platinum Sponsors











Gold Sponsors























Silver Sponsors









Trade Exhibitors









































ASTRAZENECA ONCOLOGY PORTFOLIO

Leading a revolution in oncology to redefine cancer care



LUNG CANCER









BREAST CANCER















OVARIAN & GENITOURINARY CANCER









GASTROINTESTINAL CANCERS







HAEMATOLOGY



Downloadable copies of prescribing information (PI) are available upon request, please contact AstraZeneca Sales Representative for assistance. The claim/information on this material is based on the PI approved on the date of print. Scan the QR Code for the latest PI.



























TAGRISSO

IMFINZI

IRESSA

ENHERTU

LYNPARZA

FASLODEX

ARIMIDEX NOLVADEX-D

ZOLADEX

CASODEX

IMJUDO

CALQUENCE



EMPOWERING HOPE, EXTENDING LIVES



YOUR PARTNER IN CANCER MANAGEMENT



The Goal is Cure - The Cancer Immunotherapy to Demonstrate Reduction of Recurrence in adjuvant eNSCLC.^{1,2}

The Power of Uncompromised Survival - Expand your treatment options for PD-L1-high mNSCLC with 1L TECENTRIQ. 3

Reliability When It Matters - TECENTRIQ with Carboplatin/Etoposide to Demonstrate Clinically Significant OS in ES-SCLC.⁴





A Powerful Regimen When Patients Need More -The Cancer Immunotherapy Combination to Demonstrate Meaningful OS in NSCLC with Liver Metastasis.⁵



Think Positive, Think Alecensa First - The ALK Inhibitor to Demonstrate Clinically Significant Efficacy in the CNS for ALK+ NSCLC.⁶



Reimagine Cancer Care with PHESGO - A Fixed Dose SC Injection for The Treatment of HER2+ Breast Cancer. Treatment in Minutes, not HOURS.⁷



For Women with HER2+ eBC and Residual Invasive Disease after Neoadjuvant Treatment, A Breakthrough in eBC.⁸



Neoadjuvant PERJETA-Herceptin with Chemotherapy: Part of an Efficacious Treatment Regimen for HER2+ eBC.⁹



The Strength of Overall Survival - The Cancer Immunotherapy Combination to Demonstrate Survival Benefit vs Sorafenib in 1L Unresectable or mHCC.¹⁰

ABBREVIATIONS: ALK: anaplastic lymphoma kinase; CNS: central nervous system; eBC: early breast cancer; EGFR: epidermal growth factor receptor; eNSCLC: early non-small cell lung cancer; ES-SCLC: extensive-stage small cell lung cancer; HER2: human epidermal growth factor receptor 2; mHCC: metastatic hepatocellular carcinoma; NSCLC: non-small cell lung cancer; OS: overall survival: SC: subcutaneous

REFERENCES: 1. Felip E, et al. Lancet 2021;398(10308):1344-1357; 2. ESMO Daily Reporter. 2022; 3. Herbst RS, et al. N Engl J Med 2020;383(14):1328-1339; 4. Horn L, et al. N Engl J Med 2018;379(23):2220-2229; 5. Socinski MA, et al. N Engl J Med 2018;378(24):2288-2301; 6. Peters S, et al. N Engl J Med 2017;377(9):829-838; 7. O'Shaughnessy J, et al Eur J Cancer 2021;152:223-232; 8. von Minckwitz, G, et al. N Engl J Med 2019; 380(7):617-628; 9. Gianni L, et al. Lancet 2016; 17(6):791-800; 10. Finn RS, et al. N Engl J Med 2020;382(20):1894-1905.

Roche (Malaysia) Sdn. Bhd. Co. Reg. No. 197201000194 (11792-H) Level 21, The Pinnacle, Persiaran Lagoon, Bandar Sunway, 47500 Subang Jaya, Selangor Darul Ehsan Tel: +603 - 7628 5600 malaysia.pharma@roche.com

For Healthcare Professionals Only

M-MY-00001480-06-2024 Expires: 10-06-2026 unless superseded by a new version Scan codes to access full prescribing information









ALECENSA

TECENTRIQ

Disclaimer: This information should not be used or shared or distributed to any other person/party and should be strictly by the intended parties for the intended purposes only. For more information, please refer to full prescribing information. This material contains copyright protected information, content, product/device image; thus use of which is limited by law and this material cannot be reproduced, replicated, used or modified by any person for their own use or further distribution. If you would like to have more information, or to report an adverse event regarding Avastin/PHESGO/Perjeta/Kadcyla/Alecensa/Tecentriq/Herceptin, please visit: https://medinfo.roche.com/my/en.html





Approved for 3 Indications across 3 Tumor Types¹

New Approved Product (Yervoy) and Indications in combination with nivolumab (Opdivo)

NEW ON'S



CM9LA



CM214

CM648

Non-Small Cell Lung Cancer

YERVOY in combination with **nivolumab** and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.

Renal Cell Carcinoma

YERVOY in combination with **nivolumab** is indicated for the first-line treatment of adult patients with intermediate/ poor-risk advanced renal cell carcinoma

Oesophageal Squamous Cell Carcinoma

YERVOY in combination with **nivolumab** is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥1%

Synergy of OPDIVO® AND YERVOY®

allows deep and durable anti-cancer immune responses¹⁻¹⁰


T CELLS

YERVOY® (ipilimumab)

helps activate and proliferate T cells by blocking CTLA-4 and also reduces Treg function.²⁻¹⁰

OPDIVO (nivolumab)

helps existing T cells discover the tumor by blocking PD-1.1





MEMORY T CELLS

Some of the T cells stimulated by YERVOY can become Memory T cells. Memory T cells may allow for a longterm immune response.²⁻⁷

References: 1. YERVOY NPRA approved prescribing information Nov 2023. 2. Weber JS. Hamid O. Chasalow SD. et al. Ipilimuab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J Immunother, 2012;35(1):89-97. 3. Ansel SM, Hurvitz SA, Koenig PA, et al. Phase 1 study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2009;15(20):6446-6453. 4. Farber DL, Yudanin NA, Restifo NP, Human memory T cells: generation, compartmentalization and homeostasis. Nature Rev Immunol. 2014;14:24-35. 5. Felix J, Lambert J, Roelens M, et al. Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response. Oncoimmunology. 2016;5(7):e1136045-10. 6. Pedicord VA, Montalvo W, Leiner IM, Allison JP. Single doses of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proc Natl Acad Sci USA. 2011;180(1):626-271. Picio de Coaña Y, Wolodarski M, Poschke I, et al. Ipilimumab treatment decreases monocytic MDSCs and increase in CD8 effector memory T cells in long-term survivors with advanced melanoma. Oncotarget. 2017;8(13):21539-21553. 8. Buchbinder EL, Desai A. CTLA-4 and PD-1 pathways: similarities, dierences, and implications of their inhibition. Am J Clin Oncol. 2016;39(1):88-106. 9. Selby M Englehardt J, Lu LS, et al. Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models. Poster Presentation at ASCO 2013. Abstract 3061. 10. Yervoy HSA approved Prescribing Information Sep 2023.



80 Marine Parade Road

#20-01/09 Parkway Parade Singapore 449269











NEWLY APPROVED indications in Malaysia



A Multidisciplinary Approach to Treating Your Eligible

Early-Stage^a Resectable NSCLC Patients with

a Perioperative Regimen Including KEYTRUDA®

treatment for resectable

NSCLC **KEYNOTE-671**



KEYTRUDA® is indicated for the treatment of patients with resectable (tumors ≥ 4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery.

KEYTRUDA° is Now Approved in the Perioperative **Treatment of Certain Early-Stage NSCLC**

A Key to More Posibilities for Treating **Your Patients with Certain Advanced Gastric or GEJ Adenocarcinomas**

HER2-**NEGATIVE** Gastric/GEJ Cancer **KEYNOTE-859**

KEYNOTE-811 KEYTRUDA®, in combination with trastuzumab, fluoropyrimidine and platinum-

KEYTRUDA®, in combination fluoropyrimidine and platinum-containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1.¹

containing chemotherapy, is indicated for the first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1.1

HER2-

POSITIVE

Gastric/GEJ Cancer

KEYTRUDA° is Now Approved in the Treatment of Certain Advanced Gastric or GEJ Adenocarcinomas

NSCLC = non-small cell lung cancer ^a Early-Stage: Stage II, IIIA, or IIIB (T3-4N2) (by AJCC 8th edition).

GEJ = Gastro-oesophageal junction; HER2 = Human epidermal growth factor receptor 2; PD-L1 = Programmed death ligand-1; CPS = Combine positive score Reference: 1. KEYTRUDA® Local Product Circular. Available at https://quest3plus.bpfk.gov.my/pmo2/index.php



SELECTED SAFETY INFORMATION CONTRAINDICATIONS None. PRECAUTIONS immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, including the following immune-mediated nepatitis, immune-mediated nepatitis, immune-mediated endocrinopathies, immune-mediated deverse reactions and infusion-related reactions. Other himself, immune-mediated adverse reactions reported in less than 1% of patients treated with KEYTRUDA were uveitis, myositis, Guillain-Barré syndrome, pancreatitis, encepolatisis, suprotionsis, myosthenic syndrome/myasthenia gravis (including exacerbation), myelitis, vasculitis, hypoparathyroidism and gastritis. Withhold or permanently discontinue based on seventy and type of reaction. When KEYTRUDA is given with aximbi, liver enzymes a compared to when the drugs are used in monotherapy; Irratement of patients with multiplic myelorism with a PD-1 or PD-1.1 blocking antibody in combination with a relational analogue plus dexamethasone. ADVERSE REACTIONS: Most common adverse reactions reported in a 20% of patients were. KEYTRUDA as a single agent; puritus, pyrexis, cough, dyspinea, constipation with a thailous analogue plus dexamethasone. ADVERSE REACTIONS: Most common adverse reactions reported in a 20% of patients were. KEYTRUDA as a single agent; puritus, pyrexis, cough, dyspinea, constipation with demonstration and patients. Were the common and patients with a patients with the p SELECTED SAFETY INFORMATION CONTRAINDICATIONS None. PRECAUTIONS Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue, including the following: immune-mediated pneumoniti



NOW AVAILABLE, the new 5-year follow-up data for LORVIQUA, a first-line option for ALK+ aNSCLC patients₁ from CROWN, a global, randomised, open-label, multicenter, Phase 3 trial of LORVIQUA vs crizotinib (INV-assessed) in patients with previously untreated, ALK+ locally advanced or metastatic NSCLC_{2,3}

of patients were alive and progression free

8% with crizotinib HR=0.19 (95% CI: 0.133-0.272)₁

with LORVIOUA vs

of patients remained protected from CNS progression

with LORVIQUA vs 21% with crizotinib

HR=0.06 (95% CI: 0.029-0.120)₁

patients discontinued LORVIQUA due to treatment-related adverse reactions.

The safety profile of LORVIQUA was consistent with that of the primary analysis. No new safety signals emerged after 5 years.1

LORVIQUA as monotherapy is indicated 2

- For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor. 2. For the treatment of adult patients with ALK-positive advanced NSCLC whose disease has progressed after:
- · Alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or

LORVIQUA® (Lorlatinib) Prescribing Information. Accessed on 12 May 2024.

· Crizotinib and at least one other ALK TKI.

Scan here for full Prescribing Information.

https://labeling.pfizer.com/ShowLabeling.aspx?id=17716.

- 1. Solomon BJ, Liu G, Felip E, et al. Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study. J Clin Oncol. 2024 in press. doi:10.1200/JCO.24.00581

 LORVIQUA® (Lorlatinib) Malaysia Prescribing Information. Accessed on 12 May 2024. https://labeling.pfizer.com/ShowLabeling.aspx?id=17716.
- Shaw AT, Bauer TM, de Marinis F, et al; CROWN Trial Investigators. First-line Iorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383(21):2018-2029.







Oncology

From transformative medicines that take on the toughest challenges, to biosimilar and supportive care outcome-enabling solutions we're

ADVANCING ALL ANGLES OF CARE



LUMAKRAS

(Sotorasib) 120 mg tablets











For Medical/Healthcare Professionals Only

Before prescribing, please refer to the full prescribing information, which is available upon request.


Please contact Medical Information at 1800 818 227 or medinfo.JAPAC@amgen.com for further information or any query.

Amgen Biopharmaceuticals Malaysia Sdn. Bhd. (201901011190/1320518-U)

Common Ground 1Powerhouse, Horizon Penthouse, No.1 Persiaran Bandar Utama, Bandar Utama, 47800 Petaling Jaya, Selangor, Malaysia.

Please scan QR code provided above to access product prescribing information https://www.amgen.com.mv/e_Lumakras https://www.amgen.com.my/e_Xgeva https://www.amgen.com.my/e_Vectibix https://www.amgen.com.my/e_Mvas





References: 1. AstraZeneca Sdn Bhd. Imjudo (R) (Tremelimumab) Prescribing Information. 2. Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NE.M Evid. 2022;1(8), doi:10.1056/EVIDoa2100070. 3. Sanyo B, Chan SL, Kelley RK, et al. Four-year overall survival update from the pluse 3 HIMALAVS Atloy of termelimumab plus durvalumab in unresectable hepatocellular carcinoma. Presented at:250 ESMO World Congress on al Cancer; June 28-July 1, 2023; Barcelona, Spain.

1 in 4 patients on STRIDE alive at 4 years³

The STRIDE Regimen: Single Tremelimumab Regular Interval Durvalumab

No treatment-related gastrointestinal or esophageal varices hemorrhage events were observed with STRIDE²

No EGD required prior to initiating therapy with STRIDE²



Downloadable copies of prescribing information (PI) are available upon request, please contact AstraZeneca Sales Representative for assistance. The claims/information on this material is based on Plapproved on date of print. Scan the QR code or click on the link for the latest Pl.



AstraZeneca Sdn Bhd (69730-X)
The Bousteador Tower, Level 12, No. 10, Jalan PJU 7/6, Mutiara Damansara,
47800, Petaling Jaya, Selangor, Malaysia. T: +60 3 7624 3888 F: +60 3 7624 3999
MY-15526, SEP2024 For Healthcare Professionals Only.







Gene Solutions Genomic Malaysia Sdn Bhd Common Ground, Q.016, Jaya One, The Square 72A, Jln Professor Diraja Ungku Aziz, Seksyen 13, 46200 Petaling Jaya, Selangor, Malaysia



Johnson&Johnson

Johnson & Johnson Sdn. Bhd. (Co. No. 3718-D) Level 8. The Pinnacle, Persiaran Lagoon, Bandar Sunway, 46150 Petaling Jaya, Selangor, Malaysia. Tel: +603 7661 4500 | Fax: +603 7610 0519 @2024 Johnson & Johnson Sdn. Bhd. All Rights Reserved Creation Date: Apr 2024 Ref.: CP-444371

This material is valid for one year from the creation date

For Healthcare Professionals only.
Further information is available upon requeset

Scan here for more Prescribing Information of RYBREVANT®









It's not just living longer. It's living well.



NCCN recommended National Comprehensive Cancer Network® (NCCN®) now differentiates ribociclib (KRYXANA®) as the only Category 1 preferred 1L treatment option in combination with an Al for patients with HR+/HER2- aBC, with proven significant OS BENEFIT.1

trated in the phase III MONALEESA-2 trial, with a median OS of over 5 years in postmenop

ESMO-MCBS

Highest score of any CDK4/6 inhibitor in the 1st line2-5 (based on OS, PFS, and QoL) [KRYXANA® + ET in premenopausal* patients & KRYXANA® + AI in postmenopausal patients]

•ESMC-MCBS access based on the phase III MONALESA-2 trial and the phase III MONALESA-7 trial**

*Pre/perimenopausial women treated with the combination KRYXANA+ET should be treated with a luterizing hormone-releasing hormone (LHRH) agonist according to current clinical practice standards.



- $\begin{tabular}{ll} \hline \textbf{Consistent} OS benefits in combination with AI in 1st line aBC HR+/HER2 $6-15$ \\ Proven superior efficacy vs chemotherapy in aggressive disease patients. 16 \\ \hline \end{tabular}$
- CONFIDENCE in providing patients the only CDK4/6i in Category-1
- ✓ COMFORT by improving and maintaining QoL for patient according to ESMO-MCBS.²⁻⁶
- CARE with the longest safety follow-up (6.5 years).13
- CONVENIENT once a day, one pack size for easy dose modifications.7



Novartis Corporation (Malaysia) Sdn Bhd (197101000541) Lewel 18, Imazium, No. 8, Jalan SS21/37 Damansara Uptown, 47400 Petaling Jaya, Selangor, Malaysia, Tel: +603-7682 7777 Fax: +603-7682 7000 www.novartis.com.my







ONIVYDE®: SPECIFICALLY DESIGNED TO FIGHT PANCREATIC CANCER ALONGSIDE YOUR PATIENTS

ONIVYDE® pegylated liposomal irinotecan is approved for metastatic adenocarcinoma of the pancreas in combination with 5-fluorouracil (5-FU) and leucovorin (LV), in adult patients who have progressed following gemcitabine-based therapy¹

ONIVYDE® was not evaluated for and is not indicated for use in children who are less than 18 vears old.

ONIVYDE® IS A PEGYLATED LIPOSOME SPECIFICALLY DESIGNED TO EFFECTIVELY TREAT THIS AGGRESSIVE DISEASE, WITH STRONGER GROWTH INHIBITION VS CONVENTIONAL IRINOTECAN2-1


THE ONIVYDE®+5-FU/LV REGIMEN DEMONSTRATED
ITS CLINICAL VALUE IN BOTH ITS PHASE 3
CLINICAL TRIAL AND IN CLINICAL
PRACTICE^{1,6-13}

- Significant improvement in OS, PFS, and ORR⁶⁻⁸
 Maintained quality of life⁶⁻⁹
 Well-characterized safety profile^{1,67}



ONIVYDE®+5-FU/LV IS RECOMMENDED BY ALL MAIN INTERNATIONAL GUIDELINES 15-15

TO OPTIMIZE PATIENT OUTCOMES, PLAN FOR ONIVYDE® FROM THE START®



Please refer to full prescribing information before prescribing. For Healthcare Professionals only



Access full prescribing information by scanning this QR code

SERVIER MALAYSIA SDN BHD Registration No.199701036026 (451526-M) Unit No. 25-02, Level 25, Imazium, No. 8, Jalan SS21/37, Damansara Uptown, 47400 Petaling Jaya, Selangor, Malaysia. Tel : +603 7726 3866 www.servier.com



Abbreviations: 5-FU/LV=5-fluorouracil and leucovorin; HR=hazard ratio; ORR, objective response rate; OS=overall survival; PFS=progression-free survival; QoL=quality of life.

References:

1. ONIVYDE EU Summary of Product Characteristics. Last accessed December 2022. https://www.ema.europa.eu/en/-medicines/human/ EPAR/onivyde-pegylated-liposomal 2. Lamb YN, Scott L3. Drugs. 2017;77:785-792. 3. Drummond DC et al. Cancer Res. 2006;66:3271-3277. 4. Kalra AV et al. Cancer Res. 2014;74:7003-7013. 5. Carnevale J, Ko AH. Future Oncol. 2016;1245-446. 4. Mang-Gillam A et al. Lancer. 2016;387:545-557. Vang-Gillam A et al. Eur J Cancer. 2019;108:78-87. 8. Chen LT et al. Eur J Cancer. 2019;108:78-87. 8. Chen LT et al. Eur J Cancer. 2018;105:71-78. 9. Hubner RA et al. Eur J Cancer. 2019;106:24-33. 10. Kieler M et al. Ther Adv Med Oncol. 2019;111-13. 11. Yoo C et al. Ther Adv Med Oncol. 2019;111-9. 12. Pellina A et al. ESMO. 2019;P660. 13. Imajima T et al. ESMO. 2022;P13. 14. Cui at et al. J Natl Cancer Cent. 2022;2:205-215. 15. National Health Commission of the People's Republic of China Chin J Cancer Res. 2022;4:238-255. Id. NCCN Guidelines Version 2:2021. Pancreatic Adenocarcinoma. 17. Ducreux M et al. Ann Oncol. 2015;25(suppl 5):v56-v58. 18. eUpdate Cancer of the Pancreas Treatment Recommendations. Published June 20. 2017. ESMO Guidelines Committee. Last accessed December 2022. https://www.esmo.org/Guidelines/Gastrointestinal-Cancers/ Cancer-of-the-Pancreas/eUpdate-Treatment Recommendations. 19. Okusaka T et al. Pancreas. 2020;49:326-335. 20. Kieler M et al. J Clin Med. 2020;9:1-15.



Somatuline® Autogel® 120 mg can make a difference as a 1st line anti-tumour therapy³

ENETS Consensus Guidelines⁴


The place of SSAs in the first-line treatment of advanced Neuroendocrine Tumours

- Lanreotide* is recommended as preferential first line therapy for:
 - midgut G1 and G2 tumours (Ki-67 ≤10%) irrespective of hepatic tumour load
 - pancreatic G1 and G2 tumours (Ki-67 ≤10%) irrespective of hepatic tumour load

References: 1. Somatuline ** Autogel **. Summary of Product Characteristics 2023 2. Pavel M et al. Neuroendocrinology, 2016;103(2):172-85 3. Caplin ME et al. NEJM. 2014; 371(3):224-33 4. ENETS consensus guidelines 2023 Full prescribing information is available upon request, please refer to full prescribing i FOR HEALTHCARE PROFEESIONALS USE ONLY | SOM-MY-000143 | September 2024

















Annual Scientific Congress of Malaysian Oncological Society

Contact Us

